TherapeuticsMD (NASDAQ:TXMD) Issues Earnings Results

TherapeuticsMD (NASDAQ:TXMD) released its quarterly earnings results on Tuesday. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($6.12) by $6.13, Zacks reports. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The company had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $19.77 million.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD traded up $0.01 during midday trading on Thursday, hitting $2.03. The company’s stock had a trading volume of 4,522 shares, compared to its average volume of 58,197. The firm has a market capitalization of $23.50 million, a price-to-earnings ratio of -203.00 and a beta of 0.58. The business’s fifty day simple moving average is $2.13 and its two-hundred day simple moving average is $1.97. TherapeuticsMD has a 1 year low of $0.98 and a 1 year high of $2.95.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC lifted its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the quarter. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.